Curettage with cement augmentation of large bone defects in giant cell tumors with pathological fractures in lower-extremity long bones
 by unknown
ORIGINAL ARTICLE
Curettage with cement augmentation of large bone defects in giant
cell tumors with pathological fractures in lower-extremity long
bones
Som. P. Gupta1 • Gaurav Garg2
Received: 20 May 2015 / Accepted: 30 January 2016 / Published online: 15 February 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Background Thorough curettage and cement augmenta-
tion is the procedure of choice for treating giant cell tumor
lesions, particularly those associated with large defects. Its
association with pathological fractures has not been studied
to a great extent, although a pathological fracture following
a giant cell tumor is not a contraindication to treatment by
curettage and cementation. We present our experience of
bone cementation following intralesional curettage for
treatment of giant cell tumors of the long bones of lower
limbs with associated pathological fractures.
Materials and methods A total of 38 patients who had
undergone a procedure in the weight-bearing long bones of
lower limbs were included in the study. The age of the
patients ranged from 18-79 years with a mean age of
38.57 years. The average follow-up was 102.42 months
(8.5 years) ranging from 60-186 months (5-15.5 years).
Results were based on serial radiographs showing consol-
idation of the lesion along with a subjective clinical
examination and Enneking functional evaluation noted in
the patient’s records.
Results Approximately 76 % of the lesions occurred
around the knee. The results were graded as excellent
(72 %), good (12.82 %) fair (10.25 %) and poor (5.12 %).
Four cases developed a recurrence. Apart from a few
documented complications, the lesions showed good con-
solidation and healed well.
Conclusion Giant cell tumors of the long bones of lower
limbs with an associated pathological fracture at diagnosis
can be managed with thorough curettage and cement aug-
mentation of the bone defect with a satisfactory outcome.
Level of evidence Level IV.
Keywords Giant cell tumors  Curettage  Cement
augmentation  Pathological fractures
Introduction
Curettage with cement augmentation involves thorough
curettage of a pathological lesion from the bone and filling
the residual cavity with polymethyl methacrylate (PMMA).
It is particularly useful for giant cell tumors that extend to
the subchondral area but do not usually invade the carti-
lage. Curettage and acrylic cementing for pathological
fractures was first described by Wouters in 1974, followed
by Persson et al. [1, 2]. Cementation using methyl-
methacrylate has been studied previously with good results
[3], and is the procedure of choice for surgeons treating
these lesions, particularly those which are associated with
large defects. However, its association with pathological
fractures has not been studied to a great extent, although a
pathological fracture following a giant cell tumor is not a
contraindication to treatment by curettage and cementation
[4]. Cementation provides instant stability and sufficient
quantity of filling material for the large tumor cavity.
Furthermore, its exothermic property kills tumor cells and
causes less recurrence. This study retrospectively evaluates
our experience of bone cementation following intralesional
curettage for the treatment of giant cell tumors of the long
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Methods and materials
We performed a retrospective analysis of clinical records,
radiographs and outcomes of histologically proven cases of
giant cell tumor lesions of the long bones of lower limbs
with associated pathological fractures that had undergone
curettage and filling of the defect with cement augmenta-
tion between 1998 and 2008. A total of 38 patients who had
undergone a procedure in the weight-bearing long bones of
the lower limbs were included in the study. The age of the
patients ranged from 18-79 years with a mean age of
38.57 years. There were 27 males and 11 females
Table 1 Details of patients
presenting with giant cell
tumors






1 34/M DF CB P
2* 28/F PT CE P
3 26/M DF CE P
4 22/M DF CE P
5 41/M PT EE P
6 40/F PF CE P
7 31/M PT EE P
8 33/F DF EE P
9 45/M DT CB B
10 52/M DF CE P Yes
11 18/M PT CB P
12* 47/F DF EE P
13 63/M PT CE P
14 29/F DF EE P
15 38/M PT EE P
16 39/F PF CB B Yes
17 44/M PT CE P
18 49/M PF CE P
19 41/M DF CE P
20 20/M DF EE P
21 51/M PF CE P
22 37/F PT EE P
23 23/F DF CE P
24 63/M DT CE B
25 50/F DF EE P
26 39/M PT CE P Yes
27 40/M PF CE P
28 18/M PT EE P
29* 33/M DT EE P
30 79/M DF EE P
31 54/M PT CE P
32 32/F DF CB B
33 41/M DF EE P
34 31/M PT CE P
35 36/F PT CB B
36 48/M DF CB B
37* 37/M PF EE P
38 32/M DF EE P
PF proximal femur, DF distal femur, PT proximal tibia, DT distal tibia, CB subperiosteal cortical breach,
CE cortical erosion, EE extraosseous extension, P fracture seen at presentation, B fracture developed
following biopsy
* Operated earlier with curettage and bone grafting
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(M:F ratio 2.4:1). The average follow-up was
102.42 months (8.5 years) ranging from 60-186 months
(5-15.5 years). Inclusion criteria were histologically pro-
ven giant cell tumor lesions in the long bone of lower limbs
treated with curettage and PMMA cement augmentation,
with internal fixation as necessary and a minimum follow-
up of 5 years. Patients with multiple lesions or tumors of
the proximal fibula treated by en-bloc excision, and
patients who had received adjuvant chemotherapy or
radiotherapy were excluded from the study.
Treatment files were retrieved from the clinical record
department. After careful history taking and a thorough
physical examination, the patients were subjected to true-
size antero-posterior and lateral radiographs of the patho-
logical lesion with the adjacent joint. A chest physician
was consulted to rule out pulmonary involvement for
patients aged [45 years of age. A physician was also
consulted if the anesthetist suspected a chest lesion during
the preoperative anesthesia checkup. At the time of pre-
sentation, 15 patients had extraosseous extension, 7 had
subperiosteal cortical breach, and 16 patients and cortical
erosion (Table 1). Most of the cases were Campanacci
grade II or III [5]. Measurements (cm) were taken of the
height, width and depth of the lesion and documented.
Written consent was obtained from patients before starting
treatment. As a rule, pre-operative confirmation of diag-
nosis was performed using fine-needle aspiration cytology
or open biopsy in all patients except for 11 patients who
had been biopsied at another laboratory and were later
referred to us for definitive management. Four cases were
of local recurrence following curettage and bone grafting
performed elsewhere.
The surgical technique of extensive curettage was
contemplated by entering either from the limiting cortex
or the side of erosion, as appreciated on a radiograph and
then gradually enlarging the entry to a wide cortical
window that provides visualization of the entire tumor
cavity and permits digital palpation of the inner tumor
walls. If extension of the tumor into the soft tissues was
seen, the entire pseudo-capsule was dissected circumfer-
entially and excised completely. The intraosseous tumor
bulk was scooped out completely with a large curette
until smooth cortical bony surface with punctate bleeding
was visible, ensuring the undersurface of window.
Meticulous care was taken to ensure that all the involved
bone and the possible contaminated surrounding soft tis-
sue was excised. The curetted material was re-sent for
histopathological examination. A high-speed power burr
was used in all cases. Following thorough curettage, the
resulting cavity was irrigated with hydrogen peroxide in
all cases and phenol-dipped gauze was scraped along the
cavity wall in 17 cases, followed by normal saline irri-
gation. The cavity was then dried and completely filled
with the prepared cement mass using thumb pressure,
pushing the cement into every part of the cavity. Internal
fixation was used in only one patient with a lesion in the
proximal femur associated with a femoral neck fracture,
where titanium cannulated cancellous screws were used
for fixation before cementation. Following hardening of
the cement and completion of setting time, the extra
cement was removed using a rongeur or an osteotome.
Hemostasis was achieved and closure in layers was per-
formed without a negative suction drain.
Plain radiographs were taken post-operatively. Appro-
priate antibiotics were administered and sutures were
removed after 2 weeks. Range of motion exercises of the
joint above and below the lesion were started after suture
removal. Partial weight bearing with a pair of axillary
crutches was allowed as soon as pain subsided on the
third or fourth post-operative day and continued for
2 weeks. This was followed by cane support for
3–4 weeks. After a total period of 5–6 weeks, full weight
bearing without support was allowed. Patients were fol-
lowed up every three months for 2 years and annually
thereafter with radiographs and clinical examination.
Results were based on serial radiographs showing con-
solidation of the lesion along with a subjective clinical
examination and functional outcome noted in the patient’s
records. Fracture healing was assessed clinically and
using plain radiographs [6]. Functional evaluation was
based on the Enneking functional evaluation form [7].
Results were categorized as excellent, good, fair, or poor
based on the specific numeric range assigned in the
scoring system.
Fig. 1 Antero-posterior radiograph showing an osteolytic lesion in
the proximal femur with a pathological femoral neck fracture
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Results
Two-thirds of our patients were aged between 21 and 30
years. All 38 patients had lesions in the weight-bearing
lower extremity long bones with an associated pathological
fracture. Approximately 76 % of the lesions were reported
around the knee. Various sites of lesions included proximal
femur involvement in 6 patients, distal femur in 16
patients, proximal tibia in 13 patients and distal tibia in 3
patients (Figs. 1 and 2). The largest lesion measured 10 9
9 9 6 cm and smallest lesion measured 5 9 4 9 3 cm on
plain radiographs. Nearly all lesions showed cortical
expansion and 79 % of the lesions showed extension to the
joint surface. At presentation, fractures were documented
in 32 patients, and developed following biopsy in 6
patients. Two patients (cases 10 and 26) were diagnosed
with pulmonary lesions at the time of presentation and one
patient (case 16) developed pulmonary metastasis during
the follow-up period. Among the proximal femoral lesion
group, two patients reported lesions in the neck area with
associated femoral neck fracture while the remaining 4
patients had lesions in the greater trochanter area with a
nondisplaced fracture involving the trochanteric area.
Fracture healing occurred in 33 of the 38 patients treated
with curettage and cement augmentation after a mean of
16.8 weeks (range 7-39 weeks) (Fig. 3).
Fig. 2 Radiograph showing an osteolytic lesion in the distal femur
with an associated pathological fracture
Fig. 3 Radiographs of a 34-year-old male (case 1) showing a lesion
in the distal end of the femur with a pathological fracture (a). Post-
operative radiographs showing cementation (b). Sequential follow-up
radiographs at 11 weeks showing good consolidation of the fracture
line (c). (Arrows locating the pathological fracture)
Fig. 4 Radiograph of a 40-year-old female (case 6) showing
Girdlestone resection arthroplasty with cementation seen in an
osteolytic lesion
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Three patients developed a superficial infection which
was managed with prolonged antibiotic therapy. Necrosis
of the overlying skin in the metadiaphyseal region of the
tibia was seen in one patient and treated with repeated
debridement and flap cover. Another patient treated for a
lesion in the proximal femur developed a fracture of the
cement mass 3 weeks post-operatively due to early weight
bearing. One patient who was treated for a lesion in the
distal femur developed patella-femoral arthritis in the knee
joint 10 months post-operatively. The patient was managed
conservatively for 6 months and was later advised to
undergo total knee arthroplasty; however, the patient did
not opt for surgery until the last follow-up. Four patients
developed local recurrence during the follow-up period,
which were clinically characterized by pain and radiolog-
ically by lysis or failure of development of the sclerotic rim
between the cement and cancellous bone. In two cases, one
with a lesion in the distal femur and one with a lesion in the
proximal tibia, recurrence developed after 12 months and
in other two cases, tibial recurrences were seen at 14 and
18 months following cement augmentation. All the recur-
rent lesions were of a benign nature. Magnetic resonance
imaging (MRI) evaluation was performed in all four
patients with local recurrences. Of these four recurrences,
one patient (case 29) who was operated previously with
curettage and bone grafting for a lesion in the distal tibia
again showed local recurrence. All recurrences were con-
firmed by a second surgical histopathology examination.
Alternative modes of treatment following cement aug-
mentation were employed in four of our cases. One case of
fractured cement mass in the proximal femur underwent
Girdlestone resection arthroplasty (Fig. 4). Above-knee
amputation was carried out in one patient with a local
recurrence of the lesion 1 year following primary surgery,
involving the distal femur with extensive soft-tissue
involvement. One patient who was advised to undergo
tumor prosthesis reconstruction could not afford to do so.
In two patients who had recurrences in the distal tibia, the
lower half of the tibia was excised and the limb was
reconstructed using a double fibular graft in one patient
Fig. 5 Radiograph of a 45-year-old male showing a giant cell tumor
at the lower end of the tibia with a pathological fracture (a). Antero-
posterior and lateral radiographs showing recurrence at 14 months
after curettage and cementation (b, c). Follow-up radiographs at
6.5 years of the same patient treated with dual fibular grafts (d, e)
Fig. 6 Antero-posterior and lateral radiographs of a 63-year-old male
patient (case 13) showing a distal femur turnoplasty being performed
for a recurrent lesion in the proximal tibia
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(Fig. 5), and bone lengthening and ankle arthrodesis using
the Illizarov technique was performed in the other patient
(Fig. 6). One patient with recurrence in the proximal tibia
was managed by resection of both the proximal tibia and
fibula and distal femur turnoplasty (Fig. 5). Apart from
these complications, the rest of the patients with a patho-
logical fracture treated with curettage and cement aug-
mentation healed well (Figs. 7, 8).
Using Enneking’s criteria [7] for functional evaluation,
the results were graded as excellent (72 %), good
(12.82 %), fair (10.25 %) and poor (5.12 %) (Table 2).
One patient died during the course of follow-up due to a
cause unrelated either to the lesion or surgery.
Discussion
While managing patients with a giant cell tumor, the sur-
geon must decide whether to perform an intralesional or an
en bloc resection, whether to use adjuvant therapy, and
what material to use to fill the resultant defect in the bone.
The risk of local recurrence after en bloc resection
involving the joint followed by prosthetic or allograft
reconstruction is lower than after an intralesional procedure
[6, 8, 9]. However, the risk of long-term complications
makes this treatment generally inappropriate for giant cell
tumors of bone [7–10].
Extended curettage is the commonest modality of treat-
ment for giant cell tumors but the residual large bony defect
following curettage is a major concern for the treating sur-
geon. Small defects can be left alone and the cavities fill up
with blood which coagulates to form a clot which later
becomes ossified and forms bone [11, 12]. Large defects
should be filled with bone graft or substitutes such as cement,
hydroxyapatite, or tricalcium phosphate [13]. This subse-
quently led to the evolution of intralesional curettage fol-
lowed by packing of the defect with methyl methacrylate
cement, which was first described in 1969 by Vidal et al. [14].
Curettage and acrylic cementing for pathological frac-
tures has been described previously [15]. Wuisman et al.
Fig. 7 Antero-posterior and lateral radiographs of an 18-year-old
male patient showing a giant cell tumor lesion in the proximal tibia
with a pathological fracture (a, b). Follow-up radiographs at
14.5 years after curettage and cementation showing good consolida-
tion of the lesion with no recurrence (c, d). The patient had normal
range of motion and was asymptomatic
Fig. 8 Antero-posterior and lateral radiographs of a 33-year-old female showing an extensive lesion in the distal femur with a pathological
fracture (a, b). Follow-up at 8 years after after curettage and cementation (c, d). The patient had good range of motion at the knee
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[16] treated a pathological fracture of the proximal
humerus by curettage and cement augmentation but the
cement was later removed and autogenous bone chips were
inserted. Pals and Wilkins [17] reported good results with
no recurrences in 5 patients with pathological fractures
treated by open reduction and cementing followed by
application of allograft bone chips to the hardened cement.
Studies have demonstrated the efficiency of bone
substitutes like calcium phosphate as a filling agent and
sufficient evidence exists to support the fact that the joint
function is not compromised with time even after the use of
subchondral cement [18–20]. Healing of pathological
fractures through the femoral neck is a difficult scenario, as
we report only one patient (case 6) with a fair outcome.
Furthermore, cement is not a biological material and it is
strong in compression but relatively weak when subjected
Table 2 Details of complications, alternative procedures being performed and final outcome






6 Fractured cement mass Girdlestone arthroplasty 113 Fair
7 128 Excellent
8 96 Excellent
9 Local recurrence Ankle arthrodesis with double fibular graft 78 Fair
10 Local recurrence Above knee amputation 143 Poor
11 175 Excellent
12 Infection 71 Good
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to shear and torsion. Hence, its use in lesions involving the
head and neck of the femur may result in an increased
chance of fractures through cement.
PMMA provides immediate stability that allows early
restoration of joint motion and weight bearing, and also
facilitates recognition of radiological contrast with the
surrounding bone and detection of any lytic recurrent
zone. As no stainless steel implant was used to support
the fractures in this study, MRI evaluation can be per-
formed to detect recurrences. Should recurrence occur,
this method will not compromise other surgical alterna-
tives. Moreover, its exothermic property kills tumor cells
and causes less recurrence [3, 21]. If suspicious zones are
identified, they must be curetted and the material exam-
ined histologically. The extra cavity may then be filled
with additional cement, without disturbing the main mass
of cement previously introduced. The possible disadvan-
tages of cement augmentation include infection, prema-
ture osteoarthritic changes of the adjacent joint and
chronic effusion in the joint. It may influence the rate of
bone remodeling by affecting bone metabolism and tra-
beculae may be weakened by changes in the mechanical
environment. The experience to date with PMMA has
been extremely promising with very low rates of local
recurrence.
The recurrence of giant cell tumors of bone after surgery
is statistically to be expected within the first 2 years
although late recurrences are known. Backley et al. con-
cluded in their study that the risk of local recurrence after
curettage with high-speed burr and reconstruction of the
defect with an autogenous graft or allograft bone is similar
to that observed after use with cement and other adjuvant
treatments [22]. In two larger studies, five of seventeen
patients and eight of nineteen patients had recurrence after
management with cement; these rates are equivalent to
those reported after treatment without cement [23, 24]. The
ability of PMMA to control giant cell tumors and minimize
the chances of local recurrence has been confirmed
repeatedly. The addition of phenol and hydrogen peroxide
as an adjuvant may further reduce the chance of local
recurrence. The success of local adjuvants, especially
PMMA suggests that wide en bloc excision is no longer
necessary and should not be recommended in the primary
management of giant cell tumors of bone.
Some authors have recommended subsequent removal
of cement followed by autogenous bone grafting. However,
some authors think this would be difficult and could result
in further damage to surrounding bone, including sub-
chondral and articular surfaces [25]. None of the cases in
the present series showed degenerative changes in the knee
joint except for one patient with patella-femoral arthritis;
however, the cavities were appreciably large and extended
to the subchondral bone. The absence of degenerative
changes in such cases indicates that the fear of subsequent
osteoarthritis is largely unfounded.
Pathological fractures are not a contraindication for
curettage and cement augmentation and, on the contrary,
offer early weight-bearing mobilization supported with a
functional brace. This promotes healing of the fracture
contrary to the belief that surgery will disseminate the
tumor cells into the soft tissues and adjacent joint [26]. Our
study had some limitations. As we only included cases
treated previously with this particular method, it is a sub-
jective rather than an objective outcome. Whether this
procedure should be performed immediately or can be
postponed until fracture healing cannot be deduced from
this study.
This retrospective study allows us to conclude that giant
cell tumors of the long bones of lower limbs with associ-
ated pathological fractures at diagnosis can be managed
with thorough curettage and cement augmentation of the
bone defect with a satisfactory outcome.
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